Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page ATP252-ATP252, February 1, 2025. Alzheimers Disease (AD) is the most common form of dementia and is characterized by progressive neurodegeneration and cognitive decline.

Dementia 40

Dementia Risk Factors Stroke Strokes 40

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page A139-A139, February 1, 2025. Using Cox regression analyses, we compared the risk of incident SDH among the three groups after adjustment for demographics and comorbidities. In pre-specified sensitivity analyses, patients with a diagnosis of dementia at baseline were excluded.Results:Among 8.5

Hemorrhage 40

Hemorrhage Cerebrovascular Disease Dementia Document 40

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page ADP15-ADP15, February 1, 2025. Background:White matter hyperintensities (WMH) of presumed vascular origin can be associated with vascular cognitive impairment and dementia. However, WMH are also seen in asymptomatic subjects. FLAIR/T1 images were segmented to create WMH masks.

Cerebrovascular Disease 40

Cerebrovascular Disease Dementia Risk Factors Cardiovascular Disease 40

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page AWP310-AWP310, February 1, 2025. Background:Vascular risk factors, particularly in midlife, are associated with an increased risk of dementia, and smoking has been inversely associated with Parkinson's disease (PD) risk, but the role of these factors in PD-dementia (PDD) is less clear.

Dementia 40

Dementia Risk Factors Atherosclerosis Obesity 40

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page ATP358-ATP358, February 1, 2025. Introduction:Stroke is a well-established independent risk factor for the development of dementia. Most dementia patients exhibit mixed brain pathologies, with histological evidence of ischemia and A plaque accumulation, observed at autopsy.

Dementia 40

Dementia Stroke Strokes Risk Factors 40

Stroke Journal

DECEMBER 5, 2024

Stroke, Volume 56, Issue 1 , Page 65-73, January 1, 2025. We aimed to investigate whether socioeconomic status was associated with the rate of poststroke dementia (PSD).METHODS:This PSD was defined as a dementia diagnosis in the National Patient Registry or a dispensed prescription of dementia medication after a stroke.

Dementia 40

Dementia Education Stroke Strokes 40

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page AWP285-AWP285, February 1, 2025. Introduction:Cerebral small vessel disease (CSVD) is linked to stroke and dementia risk, often predating clinical events for years to decades.

Risk Factors 40

Risk Factors Blood Pressure Dementia Stroke 40

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page ADP12-ADP12, February 1, 2025. Introduction:Stroke, dementia, and late-life depression (LLD) are age-related brain diseases that pose significant public health challenges. 0.92); dementia HRs were 0.86 (95%CI: 0.81-0.91) We used a modified 19-point BCS adapted to available UKB data.

Dementia 40

Dementia Public Health Stroke Strokes 40

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page ATP42-ATP42, February 1, 2025. Introduction:Aging and chronic cerebral hypoperfusion (CCH) are major risk factors for Vascular contribution to cognitive impairment and dementia (VCID), which is a heterogeneous group of disorders characterized by cognitive deficits secondary to cerebrovascular pathology.

Dementia 40

Dementia Stenosis Risk Factors Stroke 40

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page ATP378-ATP378, February 1, 2025. Accumulation of oxidative stress has been shown to trigger the initiation and progression of cognitive deficits, including mild cognitive impairment (MCI) and Alzheimers Dementia (AD).

BMI 40

BMI Biomarkers Dementia Stroke 40

Dr. Malcolm Kendrick

OCTOBER 30, 2024

(2022-25) Swiss Reinsurance Company: £645K China Kadoorie Biobank (2002-ongoing) AstraZeneca: $300K Bayer AG: £300K GlaxoSmithKline: £3.6M Elinogrel feasibility trial (2010-2011) Novartis: £500K EMPA-KIDNEY (2017-ongoing) Boehringer Ingelheim: £106.3M Establishing Fuwai-Oxford research centre (2010-ongoing) Merck: £1.1M

Cholesterol 145

Cholesterol Article Research Diet 145